Press Release
Arcadia Biosciences Responds to EU Court Ruling Regarding Regulation of Organisms Obtained by Mutagenesis
– Company’s health and nutrition ingredients, including GoodWheat™ platform of wheat innovations, are not affected by the ruling –
On
“Arcadia is focused on commercializing traits developed using TILLING, a non-GM mutagenesis technique developed by Arcadia scientists and widely accepted as traditional plant breeding,” said Raj Ketkar, president and CEO of Arcadia. “Our proprietary TILLING libraries and pipeline of unique traits in soybeans, vegetables and wheat, including our GoodWheat ingredients, deliver innovative nutritional benefits for consumers and production benefits for growers, and are not subject to the EU ruling.
“However, Arcadia will continue to utilize innovations like CRISPR-Cas9 to accelerate commercialization of value-added plants in regions such as the U.S., where such modern gene-editing techniques are not regulated as GMOs,” Ketkar said. “We will leverage our unique TILLING capabilities along with other technologies to commercialize consumer food ingredients and crop enhancement traits, in line with the requirements of each geographical market.”
About
Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements are subject to risks and uncertainties that
could cause actual results to differ materially, and reported results
should not be considered as an indication of future performance. These
risks and uncertainties include, but are not limited to: Arcadia’s and
its partners’ and affiliates’ ability to develop commercial products
incorporating their traits, and complete the regulatory review process
for such products; Arcadia’s compliance with laws and regulations that
impact Arcadia’s business, and changes to such laws and regulations;
Arcadia’s future capital requirements and ability to satisfy its capital
needs; and the other risks set forth in Arcadia’s filings with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20180807005296/en/
Source:
Arcadia Biosciences
Jeff Bergau, +1-312-217-0419
jeff.bergau@arcadiabio.com